Frontier Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Frontier Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-179,806	Closed	-$4.58M	–	290
2021 Q3	$4.58M	Sell	179,806 -160,626	-47%	-$4.72M	0.04%	260
2021 Q2	$11.9M	Sell	340,432 -545,868	-62%	-$21.3M	0.09%	219
2021 Q1	$36.1M	Buy	+886,300	New	+$40.7M	0.27%	128
2020 Q3	–	Sell	-92,201	Closed	-$5.82M	–	304
2020 Q2	$5.82M	Buy	92,201 +39,342	+74%	+$2.7M	0.05%	249
2020 Q1	$2.7M	Sell	52,859 -81,141	-61%	-$5.44M	0.03%	259
2019 Q4	$10.7M	Buy	134,000 +72,816	+119%	+$4.32M	0.08%	220
2019 Q3	$2.97M	Sell	61,184 -2,084	-3%	-$109K	0.02%	263
2019 Q2	$3.33M	Buy	+63,268	New	+$3.64M	0.03%	273
2018 Q2	–	Sell	-191,890	Closed	-$9.27M	–	343
2018 Q1	$9.27M	Buy	+191,890	New	+$10.7M	0.07%	243

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Frontier Capital Management's GBT Position: Q4 2021 in Review

Frontier Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2021, closing a stake of 179,806 shares — an estimated $4.58M sold.

Frontier Capital Management first reported a position in GBT in Q1 2018 and held it in 9 quarters. The position peaked at $36.1M in Q1 2021. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

Frontier Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Frontier Capital Management sold 179,806 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $4.58M.
Frontier Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 9 quarters.
Frontier Capital Management's Global Blood Therapeutics, Inc. position peaked at $36.1M in Q1 2021.
206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on Frontier Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.